Sarilumab
A human anti-IL-6R monoclonal IgG1 antibody.
General information
Sarilumab is a human monoclonal IgG1 antibody that binds to interleukin 6 receptor (IL-6R), thus blocking IL-6 mediated inflammatory response. Sarilumab is approved for the treatment of moderate to severe rheumatoid arthritis (DrugBank).
Sarilumab on Wikipedia
Synonyms
Kevzara
Supporting references
Link | Tested on | Impact factor | Notes | Publication date |
---|---|---|---|---|
Sarilumab use in severe SARS-CoV-2 pneumonia
Severe severity Preprint |
Patients | May/18/2020 | ||
Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
IL-6 Case series Antibody |
Patients | 9.91 | Potential clinical benefit in the case of early administration. Rapid improvement in respiratory function and inflammation markers in 10 out of 15 patients. Sample size: 15. Dosage: Subcutaneous injection of 400 mg; 3 of 15 patients received a second dose within 24 hours of the first. |
Aug/01/2020 |
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation
IL-6 IL-1 ARDS Severe severity Protein factor Critical severity Antibody Cohort study |
Severe pneumonia and hyper-inflammation patients | 7.56 | The therapy increased survival in patients when initiated while PaO2/FiO2 ≥ 100 mmHg (but not if lower). Sample size: 25 + 103 matched control. Dosage: A single 400 mg IV dose. |
Apr/29/2021 |
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study
IL-6 IL-1 Protein factor Antibody Cohort study |
Patients with respiratory insufficiency and hyperinflammation | 8.14 | The treatment (data pooled for Tocilizumab and Sarilumab) did not significantly reduce mortality in the studied population. It was effective in the sub-cohorts of patients with either high levels of C-reactive protein or low levels of lactate dehydrogenase, however. Sample size: 26 (+ 29 pooled with Tocilizumab) + 275 no IL-inhibitor. Dosage: A single IV dose of 400 mg. Main outcome: Survival. |
Feb/03/2021 |
Clinical trials
ID | Title | Status | Phase | Start date | Completion date |
---|---|---|---|---|---|
NCT04322773 | Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure | Terminated | Phase 2 | Apr/05/2020 | Oct/08/2020 |
|
|||||
NCT04357860 | Clinical Trial of Sarilumab in Adults With COVID-19 | Completed | Phase 2 | Apr/28/2020 | Apr/06/2021 |
|